President Cyril Ramaphosa launched Lenacapavir, a groundbreaking injectable drug for HIV prevention administered twice annually, at the Lilian Ngoyi Stadium in Secunda, Mpumalanga, marking a significant milestone in the nation's fight against HIV.
In a major development in the global fight against HIV, South Africa officially launched the rollout of Lenacapavir, a twice-yearly injectable drug designed for HIV prevention.
The launch, held on Friday at the Lilian Ngoyi Stadium in Secunda, Mpumalanga, marks a pivot point in the nation's efforts to curb new infections.
The injectable treatment offers a significant shift from the daily pill burden that has defined HIV prevention for decades. By providing powerful protection through just two doses per year, health officials hope to drastically lower barriers to adherence.
"This represents the triumph of science over despair," President Cyril Ramaphosa said, addressing the crowd.
